Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coalition to Preserve DSHEA

This article was originally published in The Tan Sheet

Executive Summary

Supplement trade groups and companies known as the Coalition to Preserve DSHEA will develop a web portal and website with resources on the Dietary Supplement Health & Education Act, an official announcement of the coalition's formation states May 6. The website will serve legislators, staff, the media and retailers with resources on DSHEA while the web portal will offer consumers the opportunity to express their opinions on the legislation to Congress and the media. The effort to educate consumers and retailers on threats to DSHEA follows the coalition's first official action in April-the submission of a citizen petition to FDA that challenged the agency's interpretation of a "dietary supplement" (1"The Tan Sheet" April 12, 2004, p. 15)...

You may also be interested in...



FDA Miscasts “Dietary Substance” In Statements On DSHEA – Petition

FDA's recently articulated interpretation of what constitutes a dietary substance "would substantially narrow the scope of the statutory definition of a dietary supplement," according to an April 8 citizen petition by supplement trade groups and companies

Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question

Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug? 

Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question

Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug? 

Topics

UsernamePublicRestriction

Register

PS096799

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel